Crystal structures of the multispecific 17beta-hydroxysteroid dehydrogenase type 5: critical androgen regulation in human peripheral tissues
- PMID: 15087468
- DOI: 10.1210/me.2004-0032
Crystal structures of the multispecific 17beta-hydroxysteroid dehydrogenase type 5: critical androgen regulation in human peripheral tissues
Abstract
Human type 5 17beta-hydroxysteroid dehydrogenase (17beta-HSD5;AKR1C3) plays a major role in the metabolism of androgens in peripheral tissues. In prostate basal cells, this enzyme is involved in the transformation of dehydroepiandrosterone into dihydrotestosterone, the most potent androgen. It is thus a potential target for prostate cancer therapy because it is understood that the testosterone formation by this enzyme is an important factor, particularly in patients who have undergone surgical or medical castration. Here we report the first structure of a human type 5 17beta-HSD in two ternary complexes, in which we found that the androstenedione molecule has a different binding position from that of testosterone. The two testosterone-binding orientations in the substrate-binding site demonstrate the structural basis of the alternative binding and multispecificity of the enzyme. Phe306 and Trp227 are the key residues involved in ligand recognition as well as product release. A safety belt in the cofactor-binding site enhances nicotinamide adenine dinucleotide phosphate binding and accounts for its high affinity as demonstrated by kinetic studies. These structures have provided a dynamic view of the enzyme reaction converting androstenedione to testosterone as well as valuable information for the development of potent enzyme inhibitors.
Similar articles
-
Structural basis of the multispecificity demonstrated by 17beta-hydroxysteroid dehydrogenase types 1 and 5.Mol Cell Endocrinol. 2006 Mar 27;248(1-2):38-46. doi: 10.1016/j.mce.2005.11.035. Epub 2006 Feb 15. Mol Cell Endocrinol. 2006. PMID: 16480815 Review.
-
Structures of complexes of type 5 17β-hydroxysteroid dehydrogenase with structurally diverse inhibitors: insights into the conformational changes upon inhibitor binding.Acta Crystallogr D Biol Crystallogr. 2015 Apr;71(Pt 4):918-27. doi: 10.1107/S1399004715002175. Epub 2015 Mar 27. Acta Crystallogr D Biol Crystallogr. 2015. PMID: 25849402
-
Androgen formation and metabolism in the pulmonary epithelial cell line A549: expression of 17beta-hydroxysteroid dehydrogenase type 5 and 3alpha-hydroxysteroid dehydrogenase type 3.Endocrinology. 2000 Aug;141(8):2786-94. doi: 10.1210/endo.141.8.7589. Endocrinology. 2000. PMID: 10919264
-
Localization of type 5 17beta-hydroxysteroid dehydrogenase, 3beta-hydroxysteroid dehydrogenase, and androgen receptor in the human prostate by in situ hybridization and immunocytochemistry.Endocrinology. 1999 Mar;140(3):1481-91. doi: 10.1210/endo.140.3.6585. Endocrinology. 1999. PMID: 10067877
-
17β-Hydroxysteroid dehydrogenases (17β-HSDs) as therapeutic targets: protein structures, functions, and recent progress in inhibitor development.J Steroid Biochem Mol Biol. 2011 May;125(1-2):66-82. doi: 10.1016/j.jsbmb.2010.12.013. Epub 2010 Dec 28. J Steroid Biochem Mol Biol. 2011. PMID: 21193039 Review.
Cited by
-
Development of potent and selective indomethacin analogues for the inhibition of AKR1C3 (Type 5 17β-hydroxysteroid dehydrogenase/prostaglandin F synthase) in castrate-resistant prostate cancer.J Med Chem. 2013 Mar 28;56(6):2429-46. doi: 10.1021/jm3017656. Epub 2013 Mar 13. J Med Chem. 2013. PMID: 23432095 Free PMC article.
-
Using biochemistry and biophysics to extinguish androgen receptor signaling in prostate cancer.J Biol Chem. 2021 Jan-Jun;296:100240. doi: 10.1074/jbc.REV120.012411. Epub 2021 Jan 9. J Biol Chem. 2021. PMID: 33384381 Free PMC article. Review.
-
AKR1C3 (type 5 17β-hydroxysteroid dehydrogenase/prostaglandin F synthase): Roles in malignancy and endocrine disorders.Mol Cell Endocrinol. 2019 Jun 1;489:82-91. doi: 10.1016/j.mce.2018.07.002. Epub 2018 Sep 19. Mol Cell Endocrinol. 2019. PMID: 30012349 Free PMC article. Review.
-
Human cytosolic hydroxysteroid dehydrogenases of the aldo-ketoreductase superfamily catalyze reduction of conjugated steroids: implications for phase I and phase II steroid hormone metabolism.J Biol Chem. 2009 Apr 10;284(15):10013-22. doi: 10.1074/jbc.M809465200. Epub 2009 Feb 12. J Biol Chem. 2009. PMID: 19218247 Free PMC article.
-
In situ proteolysis of an N-terminal His tag with thrombin improves the diffraction quality of human aldo-keto reductase 1C3 crystals.Acta Crystallogr F Struct Biol Commun. 2018 May 1;74(Pt 5):300-306. doi: 10.1107/S2053230X18005721. Epub 2018 Apr 24. Acta Crystallogr F Struct Biol Commun. 2018. PMID: 29717998 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases